MetLife (MET)
NYSEFinancialsInsurance - LifeSnapshot 2026-07-08
$91.68+1.35%
Close 2026-07-07 · 1-day change
Reading MET? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track MET free→NYSEFinancialsInsurance - LifeSnapshot 2026-07-08
Reading MET? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track MET free→A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a durable compounder with a focus on consistent earnings growth. The current thesis state is intact, supported by recent performance and management priorities.
The market currently reflects a neutral valuation, with expectations slightly below what is justified. There is a low expectations gap, indicating that the stock is priced in alignment with its fundamentals compared to peers.
Management is on track to deliver double-digit adjusted earnings per share growth and achieve variable investment income targets. However, there is a moderate risk due to the potential for guidance cuts and the overall volatility in the financial sector.
The thesis hinges on management's ability to maintain its growth trajectory and the performance of sector bellwethers. Additionally, any changes in interest rates by the Fed could significantly impact MET's performance.
Overall, MET is positioned well for the next 1 to 3 years, but attention should be paid to management execution and sector developments. Not investment advice.
The most important moves since the prior daily snapshot.
Management rose by 9.7 points (from 58.7 to 68.4).
Yes, our read has strengthened. The latest earnings beat supports a positive outlook. The company is also advancing its growth strategy through a partnership in India. Additionally, higher interest rates can boost investment income.
as of 2026-07-08
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: This report will show if MetLife continues its double-digit EPS growth trend. Investors will focus on earnings performance.
Confirms:Earnings per share growth exceeds 10% year over year in the Q2 report.
Disproves:Earnings per share growth is below 5% year over year in the Q2 report.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Adjusted earnings growth shows how well MetLife is managing its costs and investments. Strong growth supports the goal of double-digit EPS growth.
Confirms:Adjusted earnings for Q2 2026 increase year over year by more than 15%.
Disproves:Adjusted earnings for Q2 2026 grow less than 10% year over year.
Why it matters: Meeting the EPS growth target shows MetLife's ability to grow profits. This is key to investor confidence.
Confirms:Q2 EPS growth meets or exceeds 10%.
Disproves:Q2 EPS growth falls below 5%.
Why it matters: Changes in dividends show how MetLife is doing financially. They also show how MetLife plans to use its money.
Confirms one read:Announcement of an increase in preferred stock dividends for Q3 2026.
Confirms the other:Announcement of a decrease in preferred stock dividends for Q3 2026.
Why it matters: Strong investment income helps MetLife grow and stay financially healthy.
Confirms:Variable investment income is over $518 million in Q2 2026.
Disproves:Variable investment income falls below $400 million in Q2 2026.
Why it matters: A higher expense ratio may show inefficiencies. A low ratio helps make more money.
Confirms:The expense ratio for Q2 2026 is below 20%.
Disproves:The expense ratio for Q2 2026 rises above 21%.
Why it matters: A strong free cash flow ratio is key for MetLife's growth and money plans.
Confirms:Free cash flow ratio improves to above 50% in upcoming quarters.
Disproves:Free cash flow ratio drops below 30% in upcoming quarters.